deferiprone has been researched along with Heart Diseases in 14 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Heart Diseases: Pathological conditions involving the HEART including its structural and functional abnormalities.
| Excerpt | Relevance | Reference |
|---|---|---|
| "For nearly 30 years, patients with transfusional iron overload have depended on nightly deferoxamine infusions for iron chelation." | 8.83 | Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. ( Neufeld, EJ, 2006) |
| "For nearly 30 years, patients with transfusional iron overload have depended on nightly deferoxamine infusions for iron chelation." | 4.83 | Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. ( Neufeld, EJ, 2006) |
| "Combination chelation therapy with desferrioxamine and deferiprone has recently been suggested as a more effective tissue iron-chelating treatment for transfusion-dependent beta-thalassemia patients, although a standard dosage protocol has not yet been established." | 3.74 | Intensive chelation therapy in beta-thalassemia and possible adverse cardiac effects of desferrioxamine. ( Aessopos, A; Deftereos, S; Farmakis, D; Kati, M; Polonifi, E; Tsironi, M, 2007) |
| "Deferiprone, because of its lower molecular weight, might cross into heart mitochondria more efficiently, improving their activity and, thereby, myocardial cell function." | 1.39 | Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major. ( Barone, R; Calvaruso, G; Campisi, S; Capra, M; Caruso, V; Casale, M; Ciancio, A; Cianciulli, P; Cuccia, L; D'Ascola, G; Filosa, A; Gagliardotto, F; Gerardi, C; Maggio, A; Pitrolo, L; Prossomariti, L; Rigano, P; Rizzo, M; Vitrano, A, 2013) |
| "The risk of cardiac death during 1990-1999 and 2000-2008 was compared." | 1.36 | Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit. ( Berdoukas, V; Berdoussi, E; Chouliaras, G; Kattamis, C; Ladis, V; Moraitis, P; Zannikos, K, 2010) |
| "Deferoxamine (DFO) therapy has been associated with improved survival of thalassemia patients." | 1.33 | Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. ( Borgna-Pignatti, C; Cappellini, MD; Cnaan, A; De Stefano, P; Del Vecchio, GC; Forni, GL; Gamberini, MR; Ghilardi, R; Piga, A; Romeo, MA; Zhao, H, 2006) |
| "Deferiprone is an iron chelator that has the potential to be more effective than deferoxamine in removing intracellular iron from the heart." | 1.32 | Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. ( Fogliacco, E; Gaglioti, C; Piga, A; Tricta, F, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (57.14) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Filosa, A | 1 |
| Vitrano, A | 1 |
| Rigano, P | 1 |
| Calvaruso, G | 1 |
| Barone, R | 1 |
| Capra, M | 1 |
| Cuccia, L | 1 |
| Gagliardotto, F | 1 |
| Pitrolo, L | 1 |
| Prossomariti, L | 1 |
| Casale, M | 1 |
| Caruso, V | 1 |
| Gerardi, C | 1 |
| Campisi, S | 1 |
| Cianciulli, P | 1 |
| Rizzo, M | 1 |
| D'Ascola, G | 1 |
| Ciancio, A | 1 |
| Maggio, A | 1 |
| Badat, M | 1 |
| Kaya, B | 1 |
| Telfer, P | 1 |
| Ladis, V | 1 |
| Chouliaras, G | 1 |
| Berdoukas, V | 1 |
| Moraitis, P | 1 |
| Zannikos, K | 1 |
| Berdoussi, E | 1 |
| Kattamis, C | 1 |
| Musallam, KM | 1 |
| Taher, AT | 1 |
| Ammar, el-SM | 1 |
| Said, SA | 1 |
| Suddek, GM | 1 |
| El-Damarawy, SL | 1 |
| Ha, SY | 1 |
| Mok, AS | 1 |
| Chu, WC | 1 |
| Rasalkar, DD | 1 |
| Cheuk, DK | 1 |
| Chiang, AK | 1 |
| Ho, MH | 1 |
| Chan, GC | 1 |
| Westwood, M | 1 |
| Anderson, LJ | 1 |
| Pennell, DJ | 1 |
| Piga, A | 2 |
| Gaglioti, C | 1 |
| Fogliacco, E | 1 |
| Tricta, F | 1 |
| Victor Hoffbrand, A | 1 |
| Borgna-Pignatti, C | 1 |
| Cappellini, MD | 1 |
| De Stefano, P | 1 |
| Del Vecchio, GC | 1 |
| Forni, GL | 1 |
| Gamberini, MR | 1 |
| Ghilardi, R | 1 |
| Romeo, MA | 1 |
| Zhao, H | 1 |
| Cnaan, A | 1 |
| Neufeld, EJ | 1 |
| Emara, AM | 1 |
| El Kelany, RS | 1 |
| Moustafa, KA | 1 |
| Aessopos, A | 1 |
| Kati, M | 1 |
| Farmakis, D | 1 |
| Polonifi, E | 1 |
| Deftereos, S | 1 |
| Tsironi, M | 1 |
| Popelová, O | 1 |
| Sterba, M | 1 |
| Simůnek, T | 1 |
| Mazurová, Y | 1 |
| Guncová, I | 1 |
| Hroch, M | 1 |
| Adamcová, M | 1 |
| Gersl, V | 1 |
2 reviews available for deferiprone and Heart Diseases
| Article | Year |
|---|---|
Deferiprone therapy for transfusional iron overload.
Topics: Chelation Therapy; Clinical Trials as Topic; Deferiprone; Dose-Response Relationship, Drug; Heart Di | 2005 |
Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
Topics: Administration, Oral; Benzoates; beta-Thalassemia; Clinical Trials as Topic; Costs and Cost Analysis | 2006 |
1 trial available for deferiprone and Heart Diseases
| Article | Year |
|---|---|
Intermediate-term evaluation of a pratical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac t2*.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferiprone; Defero | 2011 |
11 other studies available for deferiprone and Heart Diseases
| Article | Year |
|---|---|
Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Female; Heart Diseases; Humans; Iron Chelating A | 2013 |
Combination-therapy with concurrent deferoxamine and deferiprone is effective in treating resistant cardiac iron-loading in aceruloplasminaemia.
Topics: Adult; Ceruloplasmin; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart Diseases; Humans; | 2015 |
Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit.
Topics: Adolescent; Adult; Age Factors; Benzoates; beta-Thalassemia; Child; Death; Deferasirox; Deferiprone; | 2010 |
Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia major.
Topics: beta-Thalassemia; Deferiprone; Heart Diseases; Humans; Iron Chelating Agents; Iron Overload; Magneti | 2011 |
Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats.
Topics: Aconitine; Animals; Antibiotics, Antineoplastic; Creatine Kinase, MB Form; Deferiprone; Doxorubicin; | 2011 |
Treatment of cardiac iron overload in thalassemia major.
Topics: beta-Thalassemia; Cardiomyopathies; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart Dise | 2003 |
Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Deferiprone; Deferoxamine; Disease-Free Survival; Female | 2003 |
Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Deferiprone; Deferoxamine; Female; Ferritins; Heart Dise | 2006 |
Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antioxidants; Ascorbic Acid; Deferiprone; Deferoxamine; Deoxyg | 2006 |
Intensive chelation therapy in beta-thalassemia and possible adverse cardiac effects of desferrioxamine.
Topics: beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Electrocardiography; Female; | 2007 |
Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo.
Topics: Animals; Anthracyclines; Antineoplastic Agents; Cardiotonic Agents; Cell Proliferation; Daunorubicin | 2008 |